Atrasentan

Drug Profile

Atrasentan

Alternative Names: A 147627; A-1476271; Abbott 147627; ABT-147627; ABT-627; Atrasentan hydrochloride; Xinlay

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Amides; Antineoplastics; Benzodioxoles; Carboxylic acids; Pyrrolidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic nephropathies
  • Discontinued Brain cancer; Coronary artery restenosis; Heart failure; Kidney disorders; Lung cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 28 Sep 2016 Efficacy data from the phase II S0421 trial in Prostate cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 13 Aug 2015 Phase-II was completed for Diabetic nephropathies in Japan and Puerto Rico
  • 24 Apr 2014 AbbVie initiates enrolment in a phase II trial for Diabetic nephropathies in USA (NCT02118714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top